Alyeska Investment Group
VTVT icon

Alyeska Investment Group’s vTv Therapeutics VTVT Stock Holding History

Alyeska Investment Group’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,349
Closed -$220K – 531
2018
Q1 		$220K Sell
1,349
-3,380
-71% -$827K ﹤0.01% 433
2017
Q4 		$1.14M Sell
4,729
-477
-9% -$107K 0.01% 379
2017
Q3 		$1.25M Buy
5,206
+93
+2% +$18.5K 0.01% 407
2017
Q2 		$1.02M Sell
5,113
-155
-3% -$32.3K 0.01% 406
2017
Q1 		$1.38M Sell
5,268
-62
-1% -$14.1K 0.01% 418
2016
Q4 		$1.03M Buy
5,330
+1,283
+32% +$295K 0.01% 423
2016
Q3 		$1.16M Buy
4,047
+764
+23% +$184K 0.01% 410
2016
Q2 		$762K Buy
3,283
+67
+2% +$15.4K 0.01% 396
2016
Q1 		$664K Sell
3,216
-93
-3% -$23.2K 0.01% 362
2015
Q4 		$901K Buy
3,309
+135
+4% +$37.9K 0.01% 344
2015
Q3 		$828K Buy
+3,174
New +$1.11M 0.01% 402

Other funds holding VTVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Alyeska Investment Group's VTVT Position: Q2 2018 in Review

Alyeska Investment Group sold out of vTv Therapeutics (VTVT) in Q2 2018, closing a stake of 1,349 shares — an estimated $220K sold.

Alyeska Investment Group first reported a position in VTVT in Q3 2015 and held it in 11 quarters. The position peaked at $1.38M in Q1 2017. 27 funds tracked by Wall St. Rank hold VTVT as of Q2 2018.

  • Alyeska Investment Group reported no remaining vTv Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 1,349 vTv Therapeutics shares in Q2 2018, an estimated $220K.
  • Alyeska Investment Group first reported a position in vTv Therapeutics in Q3 2015 and held it in 11 quarters.
  • Alyeska Investment Group's vTv Therapeutics position peaked at $1.38M in Q1 2017.
  • 27 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2018.

Based on Alyeska Investment Group's 13F filing for Q2 2018, filed 14 Aug 2018.